CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...
Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...
The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...
Novartis Inc. (NYSE: NVS) is intensifying its efforts to thwart the entry of generic competitors...
Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024,...
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant...
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval...
HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...
GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...
Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...
Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results...
Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic...
The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...